News about "Sandoz"

Alembic Pharma Wins USFDA Approval for Travoprost Ophthalmic Solution

Alembic Pharmaceuticals has secured USFDA approval for its Travoprost Ophthalmic Solution, with the ANDA deemed therapeutically equivalent to the reference listed drug Travatan Z (0.004%) from Sandoz.

Sandoz | 18/12/2025 | By News Bureau

Sandoz and EirGenix Ink Global Licensing Deal for Pertuzumab Biosimilar

Sandoz, the global leader in affordable medicines, has signed a global license agreement with Taiwanese biotech company EirGenix to commercialise a proposed biosimilar of the oncology medicine pertuzumab. The milestone-based deal, valued at up to USD 152 million, includes an upfront payment and potential market-based incentives.

Sandoz | 13/11/2025 | By Dineshwori |  166

Sandoz Partners with Elawan Energy to Decarbonize European Operations

Sandoz has signed a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy to co-develop 150 MW of new solar projects in Valladolid, Castilla y Leon, Spain.

Sandoz | 12/08/2025 | By Dineshwori |  171

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Sandoz | 07/08/2025 | By Dineshwori |  405

Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics

Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

Sandoz | 07/08/2025 | By Dineshwori |  405

Sandoz to Acquire Just-Evotec Biologics in USD 300 Million Deal

Sandoz has signed a non-binding term sheet with Evotec SE, paving the way for the potential acquisition of Just–Evotec Biologics EU SAS for approximately USD 300 million.

Sandoz | 30/07/2025 | By Dineshwori |  235

FDA Drug Approvals Fall in 2024, But Small Pharma Fuels Innovation Surge

The US Food and Drug Administration (FDA) approved 127 innovator and biosimilar drugs in 2024, marking a decline from the 149 approvals recorded in 2023, according to a report by leading data and analytics firm GlobalData.

Sandoz | 19/07/2025 | By Dineshwori |  381

Pharma Leaders Back UK Life Sciences Strategy, But ABPI Warns of Medicines Investment Gap

Pharmaceutical and medical technology leaders, including GSK, Sandoz, Accord Healthcare, Becton Dickinson, and Celltrion have welcomed the UK government’s new Life Sciences Sector Plan, recently unveiled as part of its flagship Industrial Strategy.

Sandoz | 19/07/2025 | By Dineshwori |  160

Biologics and Biosimilars Market: APAC Poised for Rapid Growth Driven by Rising Investments and Patient Pool

The global biologics and biosimilars market is expected to reach approximately USD 600 billion by 2032, expanding at a compound annual growth rate (CAGR) of around 6.33 percent during the forecast period.

Sandoz, | 15/07/2025 | By Dineshwori |  116

Sandoz Begins Construction Of USD 440 Million Biosimilars Production Facility In Slovenia

Sandoz is constructing a new facility in Slovenia to strengthen its European biosimilar hub and expand its global market presence.

Sandoz | 10/07/2025 | By Dineshwori |  378